Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27054278 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL18660035 | 0.77 | LMNA (0.34) | KDM4EALDH1A1HPGD | |
| SCHEMBL3786997 | 0.77 | KDM4E (0.31) | KDM4E | |
| SCHEMBL24420781 | 0.77 | ALDH1A1 (0.30) | ALDH1A1HSD17B10MAPTTSHRCASP1 | |
| SCHEMBL17119891 | 0.74 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL25970580 | 0.72 | — | — | |
| SCHEMBL2616842 | 0.72 | — | — | |
| SCHEMBL23152952 | 0.71 | KMT2A (0.33) | — | |
| SCHEMBL15215731 | 0.71 | P2RX7 (0.33) | — | |
| SCHEMBL22002659 | 0.70 | RECQL (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| US-11162104-B2 | SCN9A antisense pain killer | OLIPASS CORPORATION (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20200272872-A1 | Methods of Storing Information Using Nucleic Acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-08-27 | — | — | US | disclosed |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-11-14 | — | — | US | disclosed |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | OLIPASS CORPORATION (KR) | 2019-11-07 | — | — | US | disclosed |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2019-07-18 | — | — | US | disclosed |
| WO-2019043634-A2 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-20170337324-A1 | Methods for Retrievable Information Storage Using Nucleic Acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2017-11-23 | — | — | US | disclosed |
| US-9732110-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| US-20090131662-A1 | Compositions And Methods Pertaining To PNA Synthons And Oligomers Comprising A Universal Base | LIFE TECHNOLOGIES CORPORATION, A DELAWARE CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-7482353-B2 | Compositions and methods pertaining to PNA synthons and oligomers comprising a universal base | APPLIED BIOSYSTEMS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| EP-1307469-B1 | NUCLEIC ACID BINDING COMPOUNDS CONTAINING PYRAZOLO¬3,4-D PYRIMIDINE ANALOGUES OF PURIN-2,6-DIAMINE AND THEIR USES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1873156-A1 | Process for the preparation of 6-[[(alkoxy)carbonyl]amino]-9H-Purine-9-acetic acid and 4-[(alkoxycarbonyl)amino]-2-oxo-1(2H)-Pyrimidineacetic acid derivatives as synthons for the synthesis of peptide nucleic acids | PerSeptive Biosystems, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-7211668-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2007-05-01 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131662-A1 | Compositions And Methods Pertaining To PNA Synthons And Oligomers Comprising A Universal Base | DNMT3A, DNTT, POLI | KDM4E 4709/4885ALDH1A1 4607/4885HSD17B10 4238/4885 |
| US-20190345202-A1 | ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES | AR, NR5A1, NR5A2 | KDM4E 4345/4885ALDH1A1 2699/4885HSD17B10 532/4885 |
| US-20190337987-A1 | EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES | PTBP1, RBM17, UPF1 | KDM4E 4398/4885ALDH1A1 4196/4885HSD17B10 3248/4885 |
| US-20190218255-A1 | SCN9A ANTISENSE OLIGONUCLEOTIDES | SCN9A, SCN7A, SCN8A | KDM4E 4376/4885ALDH1A1 3949/4885HSD17B10 4043/4885 |
| US-11162104-B2 | SCN9A antisense pain killer | SCN9A, SCN7A, SCN8A | KDM4E 1281/4885ALDH1A1 3390/4885HSD17B10 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.